ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Pharmaceuticals

Japan's AGC to expand vaccine agent production for Novavax

US biotechnology firm to produce billions of doses by end of 2021

AGC Biologics, based in the U.S. city of Seattle, will supply an ingredient for Novavax's coronavirus vaccine candidate. (Photo courtesy of AGC)

TOKYO -- Japanese materials manufacturer AGC will boost production by 50% of a crucial agent in a coronavirus vaccine candidate under development by U.S. firm Novavax.

Subsidiary AGC Biologics, based in the U.S. city of Seattle, agreed to supply enough of the adjuvant component for billions of doses in 2020 and 2021. Adjuvants are agents that induce the production of antibodies, improving the individual's immune response.

To meet the extra demand, AGC Biologics will manufacture the component in Seattle, along with its facilities in Denmark.

Novavax in early August announced positive first-phase results of clinical trials in terms of safety and response to its vaccine candidate. The trials will proceed to Phase 2 as soon as this month.

In Japan, top drugmaker Takeda Pharmaceutical will make and distribute Novavax's vaccine candidate. The adjuvant by AGC, the company formerly known as Asahi Glass, may go toward Takeda's production.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more